title: [Changes in hepatic biotransformation in patients treated with beta-adrenergic drugs and prazosin].
abstract: Biotransformation in the liver was tested with antipyrine elimination test in 41 patients treated with prazosin for 3 months (Minipress Pfizer, 1-4 mg a day) or prazosin combined with beta-adrenolytic agents (propranolol 40-80 mg; metoprolol 100-200 mg daily). It was found that T0.5 of antipyrine is shortened in patients treated with prazosin alone by 3 h/p greater than .05/while in the patients treated with prazosin whom previously--adrenalytics were given by 7.5 h/p greater than 0.01/. Antipyrine half-life during the treatment with beta-adrenolytics was prolonged by + 5.3 h/p greater than .05/while during the combined therapy with these agents and prazosin - 3.8 h. These results indicate that prazosin contrary to beta-adrenolytics, does not affect biotransformation in the liver. During combined therapy with prazosin and beta-adrenolytics, unfavourable effect of the latter in prevailing. Replacement of beta-adrenolytics with prazosin may prevent unfavourable effect of the former on liver functioning and may increase the safety of the hypotensive treatment.
authors.forename: H
authors.initials: H
authors.lastname: Adamska-Dyniewska
authors.forename: S
authors.initials: S
authors.lastname: Dziekański
mesh_terms: D000328:Adult; D000368:Aged; D000983:Antipyrine / Q000493:pharmacokinetics*; D001711:Biotransformation / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000378:metabolism; D008099:Liver / Q000187:drug effects / Q000378:metabolism*; D008790:Metoprolol / Q000627:therapeutic use* / Q000633:toxicity; D008875:Middle Aged; D011224:Prazosin / Q000627:therapeutic use*; D011433:Propranolol / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D011433:Propranolol; D008790:Metoprolol; D000983:Antipyrine; D011224:Prazosin
vernacular_title: Zmiany biotransformacji watrobowej u chorych leczonych zwiazkami beta-adrenolitycznymi i prazosyna.